<DOC>
	<DOCNO>NCT00531063</DOCNO>
	<brief_summary>This extension study design provide long-term safety efficacy data beyond 12 month Month 36 .</brief_summary>
	<brief_title>This Two-year Follow-up Study Evaluate Long-term Safety , Tolerability Efficacy 2 Different Doses Everolimus</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients receive study medication Month 12 oneyear study ( CRAD001A2306 ) sign new Informed Consent extend treatment observation period beyond Month 12 . Females patient must agree continue use approved method birth control throughout study 3 month follow last dose study medication . Another Informed Consent require extension amendment . This Informed Consent allow separate consent amendment study , retrospective collection biopsy and/or yearly protocol biopsy Inclusion exclusion criterion change , except patient complete core study followup become eligible participate amend extension . Patients receive study medication sign new Informed Consent extend treatment observation period beyond Month 12 RAD001A2306 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Renal transplantation , everolimus , Immunosuppressants</keyword>
</DOC>